Immupharma PLC Result of GM (7632P)

TIDMIMM

RNS Number : 7632P

Immupharma PLC

22 February 2016

22 FEBRUARY 2016

ImmuPharma PLC

Result of GM

ImmuPharma PLC (LSE:IMM) ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, is pleased to announce that at its General Meeting today, held in connection with the Placing and Subscription, as announced on 5 February 2016, all resolutions were duly passed.

Commenting on the announcement, Tim McCarthy, Chairman of ImmuPharma, said: "We are delighted to have received such support from our existing shareholders and new investors in this placing to fund our pivotal Phase III Lupuzor(TM) trial. Having recently announced that we have commenced dosing our first Lupus patients in the US, we look forward to providing regular updates on the trial through this year and 2017."

For further information please see the Company's website, www.immupharma.org, or contact:

 
 ImmuPharma plc                                   + 44 (0) 20 7152 
  Tim McCarthy, Chairman                                      4080 
  Lisa Baderoon, Head of Investor             + 44 (0) 7721 413496 
  Relations                           lisa.baderoon@immupharma.com 
 Panmure Gordon (Financial 
  Adviser, Nominated Adviser 
  & Broker) 
  Fred Walsh, Duncan Monteith, 
  Corporate Finance 
  Charles Leigh-Pemberton, 
  Corporate Broking                           +44 (0) 20 7886 2500

All defined terms used in this announcement are defined, unless otherwise defined here, in the appendix to the Proposed Placing and Subscription and Notice of General Meeting announcement made on 5 February 2016.

This information is provided by RNS

The company news service from the London Stock Exchange

END

REGBXGDDIXDBGLD

(END) Dow Jones Newswires

February 22, 2016 08:39 ET (13:39 GMT)

Immupharma (LSE:IMM)
Historical Stock Chart
From Jun 2024 to Jul 2024